Beta-hydroxybutyrate levels and risk of diabetic ketoacidosis in adults with type 1 diabetes treated with sotagliflozin

Authors

Schafer Boeder, University of California - San Diego
Michael J Davies, Lexicon Pharmaceuticals, Inc.
Janet B McGill, Washington University School of Medicine in St. Louis
Richard Pratley, AdventHealth Translational Research Institute
Manon Girard, Lexicon Pharmaceuticals, Inc.
Phillip Banks, Lexicon Pharmaceuticals, Inc.
Jeremy Pettus, University of California - San Diego
Satish Garg, University of Colorado, Denver

Journal

Diabetes Technology & Therapeutics

Publication Date

9-1-2024

Volume

26

Issue

9

First Page

618

Last Page

625

Document Type

Open Access Publication

DOI

10.1089/dia.2023.0605

Rights and Permissions

Boeder S, Davies MJ, McGill JB, Pratley R, Girard M, Banks P, Pettus J, Garg S. Beta-Hydroxybutyrate Levels and Risk of Diabetic Ketoacidosis in Adults with Type 1 Diabetes Treated with Sotagliflozin. Diabetes Technol Ther. 2024 Sep;26(9):618-625. doi: 10.1089/dia.2023.0605. © The Author(s) 2024. Published by Mary Ann Liebert, Inc. This Open Access article is distributed under the terms of the Creative Commons License [CC-BY] (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Recommended Citation

Boeder, Schafer; Davies, Michael J; McGill, Janet B; Pratley, Richard; Girard, Manon; Banks, Phillip; Pettus, Jeremy; and Garg, Satish, "Beta-hydroxybutyrate levels and risk of diabetic ketoacidosis in adults with type 1 diabetes treated with sotagliflozin." Diabetes Technology & Therapeutics. 26, 9. 618 - 625. (2024).
https://digitalcommons.wustl.edu/oa_4/4142

Department

ICTS (Institute of Clinical and Translational Sciences)